Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7678273 | 0.91 | MAPK8 (0.58) | MAPK8LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL7317640 | 0.90 | MAPK8 (0.75) | MAPK8LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL7368970 | 0.90 | MAPK8 (0.60) | MAPK8LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL5365002 | 0.90 | MAPK8 (0.63) | MAPK8LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL5608224 | 0.89 | MAPK8 (0.52) | MAPK8LMNAHPGDSMN1; SMN2PTGER4 | |
| SCHEMBL7403963 | 0.89 | MAPK8 (0.59) | MAPK8LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL7365815 | 0.89 | MAPK8 (0.56) | MAPK8LMNAHPGDSMN1; SMN2 | |
| SCHEMBL5365180 | 0.89 | MAPK8 (0.59) | MAPK8LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL7367297 | 0.89 | MAPK8 (0.61) | MAPK8LMNAHPGDSMN1; SMN2 | |
| SCHEMBL5353948 | 0.88 | MAPK8 (0.58) | MAPK8LMNAHPGDSMN1; SMN2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050186276-A1 | Pharmaceutical formulations | PFIZER INC | 2005-08-25 | — | — | US | claimed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| EP-1519711-A1 | CONTROLLED-RELEASE PHARMACEUTICAL FORMULATIONS | Pfizer Products Inc. (US) | 2005-04-06 | — | — | EP | claimed |
| WO-2005007138-A1 | PHARMACEUTICAL FORMULATIONS | PFIZER PRODUCTS INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20040076668-A1 | Controlled-release pharmaceutical formulations | PFIZER INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004684-A1 | CONTROLLED-RELEASE PHARMACEUTICAL FORMULATIONS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | claimed |
| CN-1254335-A | Nicotinamide derivatives | PFIZER PROD INC (US) | 2000-05-24 | — | — | CN | claimed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | claimed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | claimed |
| US-8883209-B2 | Pharmaceutical solid dispersions | BEND RESEARCH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8828442-B2 | Pharmaceutical solid dispersions | BEND RESEARCH, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8481081-B2 | Pharmaceutical solid dispersions | BEND RESEARCH, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130029965-A1 | PHARMACEUTICAL SOLID DISPERSIONS | BEND RESEARCH, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20100256110-A1 | PHARMACEUTICAL SOLID DISPERSIONS | PFIZER PRODUCTS INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2004004684-A1 | CONTROLLED-RELEASE PHARMACEUTICAL FORMULATIONS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| CN-1254335-A | Nicotinamide derivatives | PFIZER PROD INC (US) | 2000-05-24 | — | — | CN | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050186276-A1 | Pharmaceutical formulations | PDE4A, PDE4B, PDE4D | MAPK8 3621/4885LMNA 3900/4885HPGD 330/4885 |
| US-20040076668-A1 | Controlled-release pharmaceutical formulations | PDE4A, PDE4B, PDE3B | MAPK8 2334/4885LMNA 2462/4885HPGD 796/4885 |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | NAMPT, NNT, XDH | MAPK8 2628/4885LMNA 1251/4885HPGD 98/4885 |
| US-20100256110-A1 | PHARMACEUTICAL SOLID DISPERSIONS | ABCG2, ABCB11, CYP2C19 | MAPK8 4132/4885LMNA 2253/4885HPGD 679/4885 |
| US-20130029965-A1 | PHARMACEUTICAL SOLID DISPERSIONS | ABCG2, GRAMD1A, CYP2C19 | MAPK8 3359/4885LMNA 2311/4885HPGD 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.